Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease

(marketscreener.com) BERWYN, Pa., Oct. 6, 2022 /PRNewswire/ -- Annovis Bio, Inc. , a late-stage clinical drug platform company addressing neurodegenerative diseases, announced today that the U.S. Food and Drug Administration has authorized the Phase 2/3 clinical study of buntanetap in moderate Alzheimer's Disease . ...https://www.marketscreener.com/quote/stock/ANNOVIS-BIO-INC-102588345/news/Annovis-Bio-Announces-FDA-Authorization-to-Proceed-with-Phase-2-3-Trial-for-Buntanetap-in-Alzheimer-41941550/?utm_medium=RSS&utm_content=20221006